Actinium Pharmaceuticals Inc (AMEX:ATNM) shares, rose in value, with the stock price down by -3.20% to the previous day’s close as strong demand from buyers drove the stock to $1.21.
Actively observing the price movement in the last trading, the stock closed the session at $1.25, falling within a range of $1.17 and $1.2399. The value of beta (5-year monthly) was -0.272. Referring to stock’s 52-week performance, its high was $10.24, and the low was $1.03. On the whole, ATNM has fluctuated by 0.00% over the past month.
With the market capitalization of Actinium Pharmaceuticals Inc currently standing at about $37.75 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-31.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ATNM’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ATNM currently trading nearly -15.59% and -4.84% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.76, while the 7-day volatility ratio is showing 9.62% which for the 30-day chart, stands at 15.20%. Furthermore, Actinium Pharmaceuticals Inc (ATNM)’s beta value is -0.11, and its average true range (ATR) is 0.16.
A comparison of Actinium Pharmaceuticals Inc (ATNM) with its peers suggests the former has fared considerably weaker in the market. ATNM showed an intraday change of -3.20% in last session, and over the past year, it shrunk by -84.37%%.
Data on historical trading for Actinium Pharmaceuticals Inc (AMEX:ATNM) indicates that the trading volumes over the past 10 days have averaged 0.36 and over the past 3 months, they’ve averaged 595.42K. According to company’s latest data on outstanding shares, there are 31.20 million shares outstanding.
Nearly 2.54% of Actinium Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 28.68% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.53 million shares as on 2025-03-31, resulting in a short ratio of 2.03. According to the data, the short interest in Actinium Pharmaceuticals Inc (ATNM) stood at 811.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.25 million. The stock has fallen by -3.97% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ATNM stock heading into the next quarter.
